As our studies have shown TGFβ-mediated upregulation of CD80 expression following the sequential passaging of tumor cells in the HS cohort, we next studied if the combination of anti-TGFβ monoclonal antibodies (mAbs) with immune the checkpoint inhibitor anti-CTLA4 mAb will impact tumor progression. This evidence concerns the gene TGFB1 and neoplasm.